CD4 and rheumatoid arthritis: Figure 3 shows an overview of how drugs currently used to treat RA, as well as therapeutics under development, may target monocytes/macrophages or their interaction with CD4+ T cells, to intervene in the underlying inflammatory and erosive disease processes.